Adocia prepares for Phase III of diabetic foot ulcer treatment
This article was originally published in Scrip
French biotechnology company Adocia has said it is actively preparing for Phase III trials of its diabetic foot ulcer treatment, BioChaperone combined with PDGF-BB (platelet-derived growth factor BB), for the second half of 2013 in the US and Europe. Simultaneously, it is planning to begin a Phase III trial in India in the fourth quarter of 2012, with a view to registering the drug in emerging countries in late 2014.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.